Variation of Serum Prostate-Specific Antigen Levels
Authors:
- James A. EasthamJEJames A. Eastham
- Elyn RiedelERElyn Riedel
- Peter T. ScardinoPSPeter T. Scardino
- Moshe ShikeMSMoshe Shike
- Martin FleisherMFMartin Fleisher
- Arthur SchatzkinASArthur Schatzkin
- Elaine LanzaELElaine Lanza
- Lianne LatkanyLLLianne Latkany
- Colin B. BeggCBColin B. Begg
- for the Polyp Prevention Trial Study GroupFGfor the Polyp Prevention Trial Study Group
Open Access
- 28 May 2003
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 289 (20) , 2695-2700
Abstract
Measurements of serum prostate-specific antigen (PSA) levels in combination with digital rectal examination have long been recommended as part of an early detection program for prostate cancer.1,2 Epidemiological data demonstrate a marked increase in the number of men diagnosed as having prostate cancer and a shift toward earlier-stage disease.3-5 While many of these men are diagnosed as having localized and therefore potentially curable tumors, there has also been a substantial increase in the number of men undergoing radical prostatectomy for small cancers that may be clinically insignificant. Epstein et al6 reviewed 157 men undergoing radical prostatectomy for clinical stage Tlc prostate cancer. Using a definition of insignificant cancer as a pathologically confined tumor with no Gleason component of 4 or 5, and a total tumor volume of less than 0.5 cm3, these investigators found that 26% of their study population had insignificant disease. Similarly, Ohori et al7 reported that 17% of men undergoing radical prostatectomy met the above definition for an insignificant tumor. These data suggest that while widespread use of PSA testing has resulted in the detection of earlier-stage cancers, many of these tumors were unlikely to be a threat to the overall health of the individual.Keywords
This publication has 17 references indexed in Scilit:
- Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, AustriaUrology, 2001
- Lowering PSA cutoffs to enhance detection of curable prostate cancerUrology, 2000
- Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable diseaseUrology, 1999
- Biological Variation of Prostate Specific Antigen Levels In Serum: An Evaluation of Day-to-Day Physiological Fluctuations in a Well-Defined Cohort of 24 PatientsJournal of Urology, 1997
- Stability of serum prostate-specific antigen determination across laboratory, assay, and storage timeUrology, 1995
- The Pathological Features and Prognosis of Prostate Cancer Detectable With Current Diagnostic TestsJournal of Urology, 1994
- Radical Prostatectomy for Impalpable Prostate Cancer: The Johns Hopkins Experience With Tumors Found on Transurethral Resection (Stages T1a and T1b) and on Needle Biopsy (Stage T1c)Journal of Urology, 1994
- Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 MenJournal of Urology, 1994
- Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference rangesJAMA, 1993
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991